health

May 2, 2026

ByteDance's Anew Labs Presents First AI-Designed Therapy as TikTok Parent Enters Drug Discovery Race

ByteDance’s drug discovery unit Anew Labs presented its first AI-designed therapy at a major immunology conference in Boston, showing a generative-AI-designed small molecule targeting IL-17, a protein-protein interaction long considered undruggable.

ByteDance's Anew Labs Presents First AI-Designed Therapy as TikTok Parent Enters Drug Discovery Race

TL;DR

  • Anew Labs, ByteDance's drug discovery unit, presented its first AI-designed therapy targeting IL-17 at an immunology conference in Boston.
  • The therapy is a small molecule designed to inhibit IL-17, a protein-protein interaction previously deemed undruggable by conventional methods.
  • Anew Labs also introduced AnewOmni, a generative AI framework trained on millions of biomolecular complexes, designed to create functional molecules across different scales.
  • ByteDance's entry into AI drug discovery aligns them with other tech companies like Isomorphic Labs, Anthropic, and Insilico Medicine.
  • The unit aims to develop oral small molecule therapies as alternatives to expensive injectable antibody treatments for autoimmune diseases.
  • AnewOmni's ability to design across scales is presented as a unique advantage, potentially overcoming limitations faced by competitors.
  • The company's drug discovery efforts leverage AI infrastructure developed for TikTok's recommendation algorithm, focusing on processing vast data to predict biological responses.
  • While promising preclinical data has been shown, the ultimate success of AI in revolutionizing drug development, and Anew Labs' role in it, will depend on clinical trial outcomes.

Continue reading the original article